laronidase
Selected indexed studies
- Laronidase. (, 2006) [PMID:29999665]
- Laronidase. (BioDrugs, 2002) [PMID:12196045]
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. (Cochrane Database Syst Rev, 2019) [PMID:31211405]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Laronidase. (2006) pubmed
- Laronidase. (2002) pubmed
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. (2019) pubmed
- Laronidase treatment of mucopolysaccharidosis I. (2005) pubmed
- Laronidase for treating mucopolysaccharidosis type I. (2007) pubmed
- Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS). (2025) pubmed
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. (2016) pubmed
- Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration. (2024) pubmed
- Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I. (2013) pubmed
- Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis. (2017) pubmed